戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  (e.g., multidrug-resistant tuberculosis and pneumococcus).
2 s species, such as Streptococcus pneumoniae (pneumococcus).
3 spiratory pathogen Streptococcus pneumoniae (pneumococcus).
4     Influenza affects host susceptibility to pneumococcus.
5  swabs yielded an alternative serotype or no pneumococcus.
6 y recombinational loss, which is frequent in pneumococcus.
7 ed on RelA after instillation of LPS but not pneumococcus.
8 cific CDS when compared to the pan-genome of pneumococcus.
9  natural resistance and cellular immunity to pneumococcus.
10 arynx, the principal ecological niche of the pneumococcus.
11 ns than control subjects who did not acquire pneumococcus.
12 ed 5157 specimens, of which 3525 (68.4%) had pneumococcus.
13  against pulmonary challenge with serotype 3 pneumococcus.
14 nges seen after infection with the wild-type pneumococcus.
15 ly involved in the innate immune response to pneumococcus.
16  fatal infections was taking prophylaxis for Pneumococcus.
17 alleled in the incidence of OM due to non-VT pneumococcus.
18 relative change in incidence of OM due to VT pneumococcus.
19 t immunity, which may ultimately benefit the pneumococcus.
20 esponse to nasopharyngeal acquisition of the pneumococcus.
21 0) of those with positive blood cultures for pneumococcus.
22 before FtsZ and guides septum positioning in pneumococcus.
23 e effectiveness of within host selection for pneumococcus.
24  a highly virulent, but immunogenic, form of pneumococcus.
25 an and infer its role in the division of the pneumococcus.
26  cholesterol-dependent cytolysin produced by pneumococcus.
27 6.11 [IQR, 20.41-76.28] FDA U/mL; P < .001), pneumococcus (17.24 [IQR, 11.33-40.25] mg/L vs 31.97 [IQ
28 vs 1.34 [IQR, 0.15-4.82] mg/L; P = .009) and pneumococcus (33.47 [IQR, 4.03-69.43] mg/L vs 50.84 [IQR
29 .7 [IQR, 27.9-168.4] FDA U/mL; P = .006) and pneumococcus (47.32 [IQR, 32.56-77.80] mg/L vs 14.77 [IQ
30                Streptococcus pneumoniae (the pneumococcus), a leading cause of bacterial disease, is
31 nown about the diversity of phages among the pneumococcus, a leading global pathogen.
32                  These findings suggest that pneumococcus activates the lipoxygenase pathway by up-re
33 , and 6 (43%) of 14 with blood cultures grew pneumococcus, all serotype 5.
34  antibody levels could not be determined for pneumococcus, almost half of the patients (47%) develope
35 d animals, compared with those infected with pneumococcus alone.
36 virus) and 3 with nonviral pathogens (2 with pneumococcus and 1 with Cryptococcus species).
37 efective in error-prone repair as well as in pneumococcus and Enterococcus faecalis UV202.
38             Introduction of vaccines against pneumococcus and Haemophilus influenzae type b (the most
39 immune system in the interaction between the pneumococcus and host.
40 w insights into the synergistic link between pneumococcus and influenza virus in the context of otiti
41  be important in the interaction between the pneumococcus and its human host.
42                     Interactions between the pneumococcus and other bacterial species alter carriage
43 nose on human glycoproteins that bind to the pneumococcus and protect the airway.
44  and selection in the population genomics of pneumococcus and provide proof of principle of the consi
45  thus discovered a novel interaction between pneumococcus and rBPI21, a potent antimicrobial peptide
46 e elapsed between the first isolation of the pneumococcus and the coming millennium, much of fundamen
47 -independent CCR mechanism identified in the pneumococcus and the first example of lethality from los
48 ation are likely to affect the spread of the pneumococcus and the rate of pneumococcal disease in the
49 olunteers that were naturally colonized with pneumococcus and, after clearance of their natural carri
50  of all strains of Streptococcus pneumoniae (pneumococcus) and induces antibodies which protect again
51 tween the pathogen Streptococcus pneumoniae (pneumococcus) and its human host is the ability of this
52 action between Streptococcus pneumoniae (the pneumococcus) and its human host.
53 RK (VicRK) TCSs of Streptococcus pneumoniae (pneumococcus) and other Streptococcus species show numer
54  reservoir for Streptococcus pneumoniae (the pneumococcus) and the source for both horizontal spread
55 y all serotypes of Streptococcus pneumoniae (pneumococcus), and all have been studied separately for
56 -shaped, ovococcal Streptococcus pneumoniae (pneumococcus), and depletion of GpsB leads to formation
57 ng 774 nonhospitalized UC, 185 (24%) yielded pneumococcus, and 70 (38%) were serotype 5.
58 colonized adults were given a type 23F or 6B pneumococcus, and a portion of these subjects became col
59 nged with WU2, a PspA(+) capsular serotype 3 pneumococcus, and its PspA(-) mutant JY1119.
60 ren globally against Haemophilus influenzae, pneumococcus, and meningococcus.
61 r a nonserotypeable isolate was or was not a pneumococcus, and the sequence of the ply gene fragment
62 ressed immunoglobulin G (IgG) levels and low pneumococcus antibody titers in a subset.
63                                Antibodies to pneumococcus are thought to represent the primary mechan
64    Infections with Streptococcus pneumoniae (pneumococcus) are a cause of significant child mortality
65    The vp1 gene is widely distributed across pneumococcus as well as encoded in related species.
66 er, the method by which neutrophils kill the pneumococcus as well as other Gram-positive bacteria, is
67 The success of Streptococcus pneumoniae (the pneumococcus) as a pulmonary pathogen is related to its
68 R mechanism and an essential activity in the pneumococcus, as an HPr point mutation abolishing HPrK/P
69  1950, the proportion of pneumonia caused by pneumococcus began to decline.
70 n(19F)-14 (ST236) to 19A ST320 has made this pneumococcus better able to colonize of the nasopharynx.
71 thal intratracheal challenge with serotype 8 pneumococcus, but it does not promote polymorphonuclear
72 ction against the homologous serotype of the pneumococcus, but the efficacies of type-specific IgM an
73  but previous attempts to study this gene in pneumococcus by generating a dpr mutant were unsuccessfu
74                                 Detection of pneumococcus by lytA polymerase chain reaction (PCR) in
75  by the 11th day, and in lungs infected with pneumococcus by the 8th day.
76  The prevalence of Streptococcus pneumoniae (pneumococcus) carriage is higher in adults who are infec
77                                           No pneumococcus cases were reported after pneumococcal and
78                    Streptococcus pneumoniae (pneumococcus) caused approximately 44000 US invasive pne
79                   Streptococcus pneumoniae ('pneumococcus') causes an estimated 14.5 million cases of
80                Streptococcus pneumoniae (the pneumococcus) causes diseases from otitis media to life-
81                    Streptococcus pneumoniae (pneumococcus) causes respiratory and systemic infections
82 e immunized with heat-killed type 3 serotype pneumococcus cells are impaired in generating pneumococc
83                Streptococcus pneumoniae (the pneumococcus) colonizes the human nasopharynx and can ca
84                   Our results show that host-pneumococcus combination was at the core of observed var
85 ficant impairment of IgM humoral response to pneumococcus compared with controls (IgM titer 79.0 vs 2
86 quenced strains of Streptococcus pneumoniae (pneumococcus) contain a version of the blp locus which i
87  Streptococcus pneumoniae, also known as the pneumococcus, contains several surface proteins that alo
88   We hypothesized that the surface charge of pneumococcus contributes to its success in nasopharyngea
89 e CSP6.1, formerly reported as an "atypical" pneumococcus, CSPps1 to reflect its occurrence in S. pse
90 3 blinded nasopharyngeal specimens that were pneumococcus culture positive, the TAC pan-pneumococcus
91 th broad protection against meningococci and pneumococcus, develop an effective vaccine against group
92  subclasses (IgG1-4), and antibody titers to Pneumococcus, diphtheria, and tetanus.
93 sed to HIV become carriers of nasopharyngeal pneumococcus earlier and more frequently than infants wh
94  or hepoxilin-A3, an eicosanoid required for pneumococcus-elicited neutrophil trans-epithelial migrat
95  We conclude that type 1 pilus expression in pneumococcus exhibits a bistable phenotype, which is dep
96                                              Pneumococcus-expressed pili are composed of three struct
97                                          The pneumococcus expresses a protease that hydrolyzes human
98                                              Pneumococcus expresses EndA during growth.
99                    Streptococcus pneumoniae (pneumococcus) expresses a capsular polysaccharide (CPS)
100                    Streptococcus pneumoniae (pneumococcus) expresses multiple, surface-exposed, choli
101 c antibody titers and subsequent carriage of pneumococcus expressing a particular antigen variant.
102 TIGR4, a serotype 4 isolate, caused discrete pneumococcus-filled microscopic lesions (microlesions),
103  how genomics has transformed the use of the pneumococcus for the pursuit of new antibiotics, and mad
104                   We assessed mortality from pneumococcus for three periods 1997-2001 (baseline), 200
105                    Streptococcus pneumoniae (pneumococcus) frequently colonizes the human nasopharynx
106       IPD cases were defined by isolation of pneumococcus from a normally sterile site in individuals
107    Invasive disease, defined as isolation of pneumococcus from a sterile site, was identified in chil
108 ing received immunizations for influenza and pneumococcus (from any source) (in 2000, 77% of MMC vs 6
109                                These include pneumococcus, group B Streptococcus, Haemophilus influen
110                  These data suggest that the pneumococcus has a major role in the development of pneu
111                                              Pneumococcus has been shown to bind to epithelial cells
112                                              Pneumococcus has continued to decline; at present, this
113            To persist in the human host, the pneumococcus has developed strategies to evade opsonizat
114 quired immunity to Streptococcus pneumoniae (pneumococcus) has long been assumed to depend on the pre
115                                         IPD (pneumococcus identified from a normally sterile site) ca
116 emic patients lacked protective responses to Pneumococcus in 14/47 (30%), diphtheria in 15%, and teta
117  showed Cryptococcus in 64 (19.5%) patients, pneumococcus in 8 (2.4%), and meningococcus in 2 (0.6%).
118 investigated human neutrophil killing of the pneumococcus in a complement-dependent opsonophagocytic
119 variance effective population size (N(e)) of pneumococcus in a mouse colonization model by monitoring
120 eumonia (MCPP) was confirmed by detection of pneumococcus in a relevant normally sterile body fluid.
121  Ne was also evident for the colonization of pneumococcus in BALB/c mice exposed to cholera toxin 4 w
122 ethal intranasal infection with a serotype 8 pneumococcus in BALB/c mice.
123 ntratracheal challenge model with serotype 8 pneumococcus in C4 KO mice.
124 -control study tested whole blood by PCR for pneumococcus in children aged 1-59 months hospitalized w
125 gh prevalence of nasal colonization with the pneumococcus in children.
126 emic and pulmonary challenge with serotype 3 pneumococcus in immunized and control mice.
127  to implement vaccines against rotavirus and pneumococcus in LMICs, and the roll out of the MenAfriVa
128       In this Review, we discuss the role of pneumococcus in the disease continuum and assess clinica
129 s essential for the host defense response to pneumococcus in the lungs and that RelA in airway epithe
130 es on immunizations, including varicella and pneumococcus in the post-vaccine era, use of a polyvalen
131          Despite routine vaccination against pneumococcus in the United States, this organism is stil
132 serum to rPstS did not inhibit growth of the pneumococcus in vitro, suggesting that antibodies do not
133 re shown to be present on the surface of the pneumococcus in vivo during pneumococcal pneumonia.
134                      NTHi 86-028NP protected pneumococcus in vivo in both the effusion fluid and bull
135 complex, kills Streptococcus pneumoniae (the pneumococcus) in a manner that shares features with acti
136  The proportion of CAP cases attributable to pneumococcus increased from 27.1% to 52.5% using that cu
137       This observation demonstrates that the pneumococcus incurs a substantial fitness cost in order
138 ccumb to challenge with live type 3 serotype pneumococcus, indicating that TACI is required for T cel
139  of AIF-specific antiserum markedly impaired pneumococcus-induced apoptosis.
140 implications for prevention and treatment of pneumococcus-induced inflammation.
141 st, ERK pathway inhibitors failed to inhibit pneumococcus-induced iNOS protein accumulation.
142 though both pathways have been implicated in pneumococcus-induced neuronal cell death, their relative
143 pneumoniae in vivo, thus implicating HXA3 in pneumococcus-induced pulmonary inflammation.
144 s (leukotrienes), but the mechanism by which pneumococcus induces production of leukotrienes in the m
145 L-6) mRNA levels peaked at 3 to 6 h for both pneumococcus-infected and NTHi-infected animals.
146 al, lower transcript levels were detected in pneumococcus-infected than in NTHi-infected animals.
147 utinin in the combined influenza A virus and pneumococcus infection cohort suggested that there were
148  have a crucial role in immunity to systemic pneumococcus infection, because both vaccinated wild-typ
149 ster of multiresistant invasive serogroup 19 pneumococcus infections, including two fatalities, was r
150  For prevention of Streptococcus pneumoniae (pneumococcus) infections in infancy, protein-conjugated
151 ith influenza virus and then challenged with pneumococcus, influenza viruses of any subtype increased
152  day after NTHi inoculation and 3 days after pneumococcus inoculation.
153 as observed in rats following inoculation of pneumococcus into the middle ear cavity.
154                                          The pneumococcus is a diverse pathogen whose primary niche i
155                                          The pneumococcus is a leading pathogen infecting children an
156                                              Pneumococcus is also a major cause of human ocular infec
157                                          The pneumococcus is one of the longest-known pathogens.
158           We conclude that a suicide gene of pneumococcus is spxB, which induces an apoptosis-like de
159                                              Pneumococcus is the most common and aggressive cause of
160                               Interestingly, pneumococcus is the only bacterium known to adhere to an
161                Streptococcus pneumoniae (the pneumococcus) is a common commensal inhabitant of the na
162                Streptococcus pneumoniae (the pneumococcus) is a human pathogen, accounting for massiv
163                    Streptococcus pneumoniae (pneumococcus) is a leading cause of bacterial meningitis
164                    Streptococcus pneumoniae (pneumococcus) is a leading human respiratory pathogen th
165                Streptococcus pneumoniae (the pneumococcus) is a major cause of bacterial pneumonia, m
166                Streptococcus pneumoniae (the pneumococcus) is a major human pathogen and a leading ca
167                    Streptococcus pneumoniae (pneumococcus) is a major human pathogen causing pneumoni
168                    Streptococcus pneumoniae (pneumococcus) is a major human pathogen, which evolved n
169                    Streptococcus pneumoniae (pneumococcus) is a major human pathogen.
170                    Streptococcus pneumoniae (pneumococcus) is a pathogen that causes severe local and
171                    Streptococcus pneumoniae (pneumococcus) is a significant pathogen that frequently
172                    Streptococcus pneumoniae (pneumococcus) is an opportunistic bacterial pathogen res
173                    Streptococcus pneumoniae (pneumococcus) is an oval-shaped, symmetrically dividing
174                    Streptococcus pneumoniae (pneumococcus) is both a widespread nasal colonizer and a
175                Streptococcus pneumoniae (the pneumococcus) is capable of invading the heart.
176                Streptococcus pneumoniae (the pneumococcus) is carried in the nasopharynx of healthy i
177 petence regulon of Streptococcus pneumoniae (pneumococcus) is crucial for genetic transformation.
178 s of the bacterium Streptococcus pneumoniae (pneumococcus) is its transmission from host to host, the
179 pulmonary pathogen Streptococcus pneumoniae (pneumococcus) is required for both genetic transformatio
180                Streptococcus pneumoniae (the pneumococcus) is the leading cause of community-acquired
181                    Streptococcus pneumoniae (pneumococcus) is the primary cause of bacterial meningit
182                Streptococcus pneumoniae (the pneumococcus) is the world's foremost bacterial pathogen
183                Streptococcus pneumoniae, the pneumococcus, is the most common cause of sepsis and men
184 a-associated hospitalizations and IPP cases (pneumococcus isolated from normally sterile sites with d
185 e opaque phenotype was predominant among the pneumococcus isolates from the middle-ear fluid in the c
186 andard microbiological methods were used for pneumococcus isolation and serotyping.
187 man mAbs to the major surface antigen of the pneumococcus, its capsular polysaccharide, and tested th
188 atory tract of mice with influenza virus and pneumococcus leads to synergistic stimulation of type I
189 ecimens but also by the misidentification of pneumococcus-like viridans group streptococci (P-LVS) as
190 e pneumococcus culture positive, the TAC pan-pneumococcus lytA assay was positive in 21 (91% sensitiv
191                    The outer cell surface of pneumococcus may assume various degrees of negative char
192 rate that morphological heterogeneity in the pneumococcus may promote colonization of the upper respi
193                                              Pneumococcus, meningococcus, and Haemophilus influenzae
194 ewborns represent a consistent population of pneumococcus-naive individuals in which to estimate the
195 data, which underscore the plasticity of the pneumococcus, need to be confirmed with in vivo analyses
196 of infants against Streptococcus pneumoniae (pneumococcus) needs substantial investment by government
197 ch serine protease is sufficient to kill the pneumococcus, none is essential.
198 gen test, or whole-blood lytA rtPCR revealed pneumococcus or if lytA rtPCR from NP swabs gave a resul
199 nations (OR, 4.25; 95% CI, 2.10-8.60), adult pneumococcus or tetanus vaccinations (OR, 5.14; 95% CI,
200  than in those who were culture negative for pneumococcus (P<.05).
201                     Results suggest that the pneumococcus phase varies between a virulent form with m
202                            Colonization with pneumococcus (PNC), which primes for memory cell respons
203 e important in predicting how changes in the pneumococcus (Pnc)-specific B-cell repertoire will influ
204                    Streptococcus pneumoniae (pneumococcus) produces hydrogen peroxide as a by-product
205                    Streptococcus pneumoniae (pneumococcus) produces many capsule types that differ in
206       These patients should receive lifelong pneumococcus prophylaxis.
207 regation, and division site selection in the pneumococcus, providing a simple way to ensure equally s
208               The Scottish Meningococcus and Pneumococcus Reference Laboratory (SMPRL) provides a nat
209       We assessed the effect of PCV13 use on pneumococcus-related admissions to hospital 2 years afte
210 echanisms underlying the lethality caused by pneumococcus remain elusive.
211 e vaccine era, Streptococcus pneumoniae (the pneumococcus) remains a leading cause of otitis media, a
212                    Streptococcus pneumoniae (pneumococcus) remains a significant health threat worldw
213                                              Pneumococcus resists beta-lactams by expressing variants
214  between a respiratory virus protein and the pneumococcus resulting in increased bacterial virulence
215 mes caused by Haemophilus influenzae type b, pneumococcus, rotavirus, and early infant influenza.
216 transporter is likely unique and integral to pneumococcus's strategy of carbon catabolite repression
217 rom bacterial carriage to infection with the pneumococcus serving as a model organism.
218 ch as the pathogen Streptococcus pneumoniae (pneumococcus), side-wall (peripheral) peptidoglycan (PG)
219 ruption in IgA expression, it was found that pneumococcus-specific IgA played a significant role in t
220                                              Pneumococcus (Streptococcus pneumoniae) remains a signif
221                                          The pneumococcus (Streptococcus pneumoniae), an important hu
222 of pneumonic lesions, using a bioluminescent pneumococcus, suggested that the effect of NA inhibition
223 ant from degranulated neutrophils killed the pneumococcus, suggesting a role for granular products.
224                                 In addition, pneumococcus synthesizes copious amounts of AcP and hydr
225 spiratory pathogen Streptococcus pneumoniae (pneumococcus) synthesizes AcP by the conventional pathwa
226 er in children who were culture positive for pneumococcus than in those who were culture negative for
227                                       In the pneumococcus, the coordinated secretion of pili from the
228      As discussed here in the context of the pneumococcus, the study of PavB highlights the central r
229         Hydrogen peroxide is produced by the pneumococcus through the action of pyruvate oxidase (Spx
230 ty by tyrosine phosphorylation may allow the pneumococcus to adapt to the requirements of both coloni
231 mplex regulation of pneumocins may allow the pneumococcus to reserve the secretion of active peptides
232 man pathobiont Streptococcus pneumoniae (the pneumococcus) to cause severe invasive infections.
233 covalently to the surface polysaccharides of pneumococcus type 14, Shigella flexneri type 2a, and Esc
234 re intranasally inoculated with 10(3) cfu of pneumococcus type 3 or type 19F and placed in a cage con
235 mutation in either comC or luxS rendered the pneumococcus unable to produce early biofilms on HREC.
236                                          The pneumococcus undergoes spontaneous phase variation betwe
237 es tested were naive responses to rabies and pneumococcus vaccines, delayed-type hypersensitivity ski
238                                              Pneumococcus was considered the cause of CAP in HIV-infe
239                                              Pneumococcus was detected by lytA rtPCR from sputum in 1
240  of proteins from a pspA-deficient strain of pneumococcus was eluted in a choline-dependent fashion.
241        Nasopharyngeal carriage prevalence of pneumococcus was monitored in prospective studies of Bed
242                                       Type 3 pneumococcus was more commonly isolated from patients wi
243                                              Pneumococcus was not detected in the blood of D11-treate
244                                       Type 3 pneumococcus was the most commonly identified serotype.
245 e variation in Streptococcus pneumoniae (the pneumococcus) was investigated.
246                        NTHi 86-028NP bla and pneumococcus were both recovered from the surface-associ
247 ved from choline-binding protein A (CbpA) of pneumococcus were identified and then genetically fused
248 imals, and animals infected with listeria or pneumococcus, were 2.3, 2.5, and 2.6, respectively.
249  much greater C3 deposition onto the PspA(-) pneumococcus when exposed to normal mouse serum from wil
250 e supernatant (CCS) from a type 14 strain of pneumococcus which contained secreted pneumococcal prote
251 ation of the multiple adhesive properties of pneumococcus which, in turn, may correlate to diminished
252 synergism exists between influenza virus and pneumococcus, which likely accounts for excess mortality
253       Identification of the lic genes in the pneumococcus will facilitate further characterization of
254  (PG) synthesis in Streptococcus pneumoniae (pneumococcus); yet, mechanisms of this switching remain

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top